From the Research
The 5-year survival rate for hepatoblastoma is approximately 80% for all patients combined, with survival rates ranging from 90% for localized disease to 50% for metastatic disease, as reported in the most recent study 1. The survival rate for hepatoblastoma varies significantly based on disease stage and treatment response.
- For localized disease that can be completely removed surgically, survival rates are excellent at 90%
- Children with more advanced disease that has spread beyond the liver (metastatic) have lower survival rates of approximately 30-70%, depending on treatment response. The standard treatment approach includes surgical resection when possible, combined with chemotherapy (typically cisplatin-based regimens such as cisplatin/doxorubicin or cisplatin/5-fluorouracil/vincristine) 2.
- Liver transplantation may be necessary for extensive tumors that cannot be resected. Early diagnosis significantly improves outcomes, with tumor stage and PRETEXT classification (a staging system specific to liver tumors) being important prognostic factors 3.
- Children with certain genetic conditions like Beckwith-Wiedemann syndrome require surveillance due to increased hepatoblastoma risk. Regular follow-up after treatment is essential to monitor for recurrence and late effects of therapy, as noted in a study on refractory or recurrent hepatoblastoma 4. The most recent and highest quality study 1 provides the best estimate of the 5-year survival rate for hepatoblastoma, and its findings should be prioritized in clinical decision-making.